News

Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."

Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida

Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.

According to the company, GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals.

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March.

This year at ARVO, Emily Chew, MD, was awarded the Proctor Award Lecture. She spoke with the Eye Care Network about this lecture and what the award meant to her.

This year at ARVO, Anand Swaroop, PhD, was awarded the Friedenwald Award Lecture 2024. He spoke with the Eye Care Network about this lecture and what the award meant to him.

Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.

David Eichenbaum, MD, spoke with Modern Retina about the phase 3 trial of sozinibercept at the 2024 Retina World Congress meeting.

Modern Retina spoke with Paulo-Eduardo Stanga, MD, from The Retina Clinic London, London, United Kingdom at the 2024 Retina World Congress meeting.

Christine Kay, MD, spoke with Modern Retina to share insights from her presentation on longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy For retinitis pigmentosa

David Almeida, MD, PhD, MBA, presented on gene therapy associated uveitis at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

At this year's ARVO meeting, the Eye Care Network spoke with Daniel Saben PhD, who is being awarded the Cogan Lecture at this year's event.

Sunir Garg, MD, FACS, shares strategies to minimize pain with intravitreal injections.

Modern Retina spoke with Veeral Sheth, MD, MBA, FASRS, FACS, at the 2024 Retina World Congress meeting about the PRISM study, 4DMT's gene therapy trial for wet AMD.

Michael A. Singer, MD, shares details about the an IRIS database look at Triamcinolone Acetonide.

Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium."

At this year's ARVO meeting, Paul Kayne, PhD, gave insight on his paper titled "Mapping the melanocortin receptors in the human eye."

At this year's ARVO meeting, Deborah A Ferrington, MD, PhD, presented "Genotype-specific differences in mitochondrial function specific to the CFH Y402H risk allele associated with AMD."

In a retrospective interventional cohort study, the investigators analyzed the outcomes of 80 patients with submacular hemorrhages who were treated with subretinal aflibercept or intravitreal aflibercept.

At this year's ARVO meeting, Allen Ho, MD, presented a paper on presenting a paper on the 12 month results of a mutation agnostic optogenetic program for patients with severe vision loss from retinitis pigmentosa.

At this year's ARVO meeting, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning-based retina segmentation tool using the Phase 2 BOULEVARD study.

Several presentations at Retina World Congress 2024 highlight the importance of diversity equity and inclusion in the retina field.